173 related articles for article (PubMed ID: 27052640)
1. Pharmacotherapies for the treatment of glioblastoma - current evidence and perspectives.
Seystahl K; Gramatzki D; Roth P; Weller M
Expert Opin Pharmacother; 2016 Jun; 17(9):1259-70. PubMed ID: 27052640
[TBL] [Abstract][Full Text] [Related]
2. Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?
Seystahl K; Weller M
Expert Opin Investig Drugs; 2012 May; 21(5):605-17. PubMed ID: 22413865
[TBL] [Abstract][Full Text] [Related]
3. Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.
Nabors LB; Fink KL; Mikkelsen T; Grujicic D; Tarnawski R; Nam DH; Mazurkiewicz M; Salacz M; Ashby L; Zagonel V; Depenni R; Perry JR; Hicking C; Picard M; Hegi ME; Lhermitte B; Reardon DA
Neuro Oncol; 2015 May; 17(5):708-17. PubMed ID: 25762461
[TBL] [Abstract][Full Text] [Related]
4. Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results.
Scaringi C; Minniti G; Caporello P; Enrici RM
Anticancer Res; 2012 Oct; 32(10):4213-23. PubMed ID: 23060541
[TBL] [Abstract][Full Text] [Related]
5. [Association of radiotherapy and chemotherapy-targeted therapies in glioblastomas].
Laigle-Donadey F; Dehais C; Mazeron JJ; Sanson M
Bull Cancer; 2009 Mar; 96(3):291-7. PubMed ID: 19318307
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.
Hainsworth JD; Shih KC; Shepard GC; Tillinghast GW; Brinker BT; Spigel DR
Clin Adv Hematol Oncol; 2012 Apr; 10(4):240-6. PubMed ID: 22706484
[TBL] [Abstract][Full Text] [Related]
7. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
Stupp R; Hegi ME; Neyns B; Goldbrunner R; Schlegel U; Clement PM; Grabenbauer GG; Ochsenbein AF; Simon M; Dietrich PY; Pietsch T; Hicking C; Tonn JC; Diserens AC; Pica A; Hermisson M; Krueger S; Picard M; Weller M
J Clin Oncol; 2010 Jun; 28(16):2712-8. PubMed ID: 20439646
[TBL] [Abstract][Full Text] [Related]
8. Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial.
Khasraw M; Lee A; McCowatt S; Kerestes Z; Buyse ME; Back M; Kichenadasse G; Ackland S; Wheeler H
J Neurooncol; 2016 May; 128(1):163-171. PubMed ID: 26935578
[TBL] [Abstract][Full Text] [Related]
9. Current therapeutic options for glioblastoma and future perspectives.
Aquilanti E; Wen PY
Expert Opin Pharmacother; 2022 Oct; 23(14):1629-1640. PubMed ID: 36100970
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab for the treatment of high-grade glioma: an update after phase III trials.
Khasraw M; Ameratunga M; Grommes C
Expert Opin Biol Ther; 2014 May; 14(5):729-40. PubMed ID: 24655021
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of dose-escalating metronomic temozolomide plus bevacizumab and bortezomib for patients with recurrent glioblastoma.
McCracken DJ; Celano EC; Voloschin AD; Read WL; Olson JJ
J Neurooncol; 2016 Oct; 130(1):193-201. PubMed ID: 27502784
[TBL] [Abstract][Full Text] [Related]
12. Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.
Alshami J; Guiot MC; Owen S; Kavan P; Gibson N; Solca F; Cseh A; Reardon DA; Muanza T
Oncotarget; 2015 Oct; 6(32):34030-7. PubMed ID: 26423602
[TBL] [Abstract][Full Text] [Related]
13. What role should cilengitide have in the treatment of glioblastoma?
Chamberlain MC
J Clin Oncol; 2010 Nov; 28(33):e695; author reply e696-7. PubMed ID: 20975074
[No Abstract] [Full Text] [Related]
14. Drug Insight: temozolomide as a treatment for malignant glioma--impact of a recent trial.
Mason WP; Cairncross JG
Nat Clin Pract Neurol; 2005 Dec; 1(2):88-95. PubMed ID: 16932504
[TBL] [Abstract][Full Text] [Related]
15. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Stupp R; Hegi ME; Mason WP; van den Bent MJ; Taphoorn MJ; Janzer RC; Ludwin SK; Allgeier A; Fisher B; Belanger K; Hau P; Brandes AA; Gijtenbeek J; Marosi C; Vecht CJ; Mokhtari K; Wesseling P; Villa S; Eisenhauer E; Gorlia T; Weller M; Lacombe D; Cairncross JG; Mirimanoff RO; ;
Lancet Oncol; 2009 May; 10(5):459-66. PubMed ID: 19269895
[TBL] [Abstract][Full Text] [Related]
16. Glioblastoma Treatment: State-of-the-Art and Future Perspectives.
Rodríguez-Camacho A; Flores-Vázquez JG; Moscardini-Martelli J; Torres-Ríos JA; Olmos-Guzmán A; Ortiz-Arce CS; Cid-Sánchez DR; Pérez SR; Macías-González MDS; Hernández-Sánchez LC; Heredia-Gutiérrez JC; Contreras-Palafox GA; Suárez-Campos JJE; Celis-López MÁ; Gutiérrez-Aceves GA; Moreno-Jiménez S
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806212
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy.
Saran F; Chinot OL; Henriksson R; Mason W; Wick W; Cloughesy T; Dhar S; Pozzi E; Garcia J; Nishikawa R
Neuro Oncol; 2016 Jul; 18(7):991-1001. PubMed ID: 26809751
[TBL] [Abstract][Full Text] [Related]
18. What have we learned from trials on antiangiogenic agents in glioblastoma?
Soffietti R; Trevisan E; Rudà R
Expert Rev Neurother; 2014 Jan; 14(1):1-3. PubMed ID: 24417499
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy of cilengitide with belotecan against experimental glioblastoma.
Kim YH; Lee JK; Kim B; DeWitt JP; Lee JE; Han JH; Kim SK; Oh CW; Kim CY
Int J Cancer; 2013 Aug; 133(3):749-56. PubMed ID: 23354807
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma.
Badruddoja MA; Pazzi M; Sanan A; Schroeder K; Kuzma K; Norton T; Scully T; Mahadevan D; Ahmadi MM
Cancer Chemother Pharmacol; 2017 Oct; 80(4):715-721. PubMed ID: 28808777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
